1-3 of 3
Johan Vansteenkiste
Close
Sort by
Journal Articles

Risk of Adverse Events Is Similar in Patients (Pts) Who Did or Did Not Achieve Hemoglobin (Hb) Above 12g/dL in a Phase 3 Clinical Trial of Darbepoetin alfa (DA) Administered Weekly (QW) or Every 3 Weeks (Q3W) in Anemic Cancer Pts Receiving Chemotherapy.

Heinz Ludwig, MD, Jean-Luc Canon, MD, Johan Vansteenkiste, MD, PhD, Lisa Hamilton, MSc, Tamás Suto, MD, PhD
Journal: Blood
Blood (2007) 110 (11): 4086.
https://doi.org/10.1182/blood.V110.11.4086.4086
Published: 2007
Journal Articles

Effects of Dose Adjustment Rules on Safety during Erythropoietic Therapy: A Retrospective Analysis of Darbepoetin alfa Administered Either Every 3 Weeks or Weekly.

Michael Hedenus, Jean-Luc Canon, Dusan Kotasek, Tom Lillie, Lisa Hendricks, Bin Yao, Johan Vansteenkiste
Journal: Blood
Blood (2005) 106 (11): 3376.
https://doi.org/10.1182/blood.V106.11.3376.3376
Published: 2005
Journal Articles

Effect of Dose Reductions on Response to 500-μg Darbepoetin alfa Administered Once Every 3 Weeks for the Treatment of Chemotherapy-Induced Anemia: Analysis from a Randomized, Double-Blind, Active-Controlled Trial.

Jean-Luc Canon, MD, Johan Vansteenkiste, MD, Gyorgy Bodoky, MD, Ma Victoria Mateos, MD, Laurent Bastit, MD, Irene Ferreira, PhD, Tom Lillie, MD
Journal: Blood
Blood (2005) 106 (11): 3558.
https://doi.org/10.1182/blood.V106.11.3558.3558
Published: 2005